Copyright
©2014 Baishideng Publishing Group Inc.
World J Gastroenterol. Oct 14, 2014; 20(38): 13741-13755
Published online Oct 14, 2014. doi: 10.3748/wjg.v20.i38.13741
Published online Oct 14, 2014. doi: 10.3748/wjg.v20.i38.13741
Patients | Phase | Treatment | n | OS (m) | PFS (m) | RR | DCR |
Previously untreated advanced gastric cancer (EXPAND) | III | Capecitabine + cisplatin | 449 | 10.7 | 5.6 | 29% | 71% |
Capecitabine + cisplatin + cetuximab | 455 | 9.4 | 4.4 | 30% | 73% | ||
Untreated metastatic or locally advanced oesophagogastric adenocarcinoma (REAL 3) | III | EOC (epirubicin + oxaliplatin + capecitabine) | 275 | 11.3 | 6.0 | 42% | 63% |
Modified dose EOC + panitumumab | 278 | 8.8 | 7.4 | 46% | 64% |
- Citation: Aoyagi K, Kouhuji K, Kizaki J, Isobe T, Hashimoto K, Shirouzu K. Molecular targeting to treat gastric cancer. World J Gastroenterol 2014; 20(38): 13741-13755
- URL: https://www.wjgnet.com/1007-9327/full/v20/i38/13741.htm
- DOI: https://dx.doi.org/10.3748/wjg.v20.i38.13741